Evidence map›Paper›PMID 33636137›Full record

Observational studyAmerican heart journal2021

Does study subject diversity influence cardiology research site performance?: Insights from 2 U.S. National Coronary Stent Registries.

Wayne B Batchelor, Abdulla A Damluji, Celina Yong, Mona Fiuzat, Scott D Barnett, David E Kandzari, Matthew W Sherwood, Kelly C Epps, Behnam N Tehrani, Dominic J Allocco and 4 more

2 registry-linked trialsOpen access · greenAbstract readObservational Study
In one paragraph

Observational study in American heart journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01589978 phase4completednot on this map

A U.S. Post-Approval Study of the PROMUS Element™ Plus Everolimus-Eluting Platinum Chromium Coronary Stent System

TypeinterventionalSponsorBoston Scientific CorporationRan2012 to 2018Enrolled2,681ConditionsCoronary Artery DiseaseArmsPROMUS Element Plus Coronary Stent System, Aspirin, P2Y12 antagonist
NCT02240810 completednot on this map

PLATINUM Diversity: Outcomes With the Promus PREMIER™ Stent in Women and Minorities (S2326)

Typeobservational_patient_registrySponsorBoston Scientific CorporationRan2014 to 2016Enrolled1,501ConditionsAtherosclerosis, Coronary Artery DiseaseArmsPercutaneous coronary intervention (Promus PREMIER)
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 1 country.

Wayne B BatchelorInova Center of Outcomes Research, Inova Heart and Vascular Institute, Falls Church, VA. Electronic address: wayne.batchelor@inova.org.
Abdulla A DamlujiInova Center of Outcomes Research, Inova Heart and Vascular Institute, Falls Church, VA.
Celina YongDivision of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA.
Mona FiuzatDepartment of Medicine, Duke University School of Medicine, Durham, NC.
Scott D BarnettInova Center of Outcomes Research, Inova Heart and Vascular Institute, Falls Church, VA.
David E KandzariPiedmont Heart Institute, Atlanta, GA.
Matthew W SherwoodInova Center of Outcomes Research, Inova Heart and Vascular Institute, Falls Church, VA.
Kelly C EppsInova Center of Outcomes Research, Inova Heart and Vascular Institute, Falls Church, VA.
Behnam N TehraniInova Center of Outcomes Research, Inova Heart and Vascular Institute, Falls Church, VA.
Dominic J AlloccoBoston Scientific Corp Marlborough MA.
Ian T MeredithBoston Scientific Corp Marlborough MA.
JoAnn LindenfeldVanderbilt University Medical Center, Nashville, TN.
Christopher M O'ConnorInova Center of Outcomes Research, Inova Heart and Vascular Institute, Falls Church, VA; Department of Medicine, Duke University School of Medicine, Durham, NC.
Roxana MehranMount Sinai Medical Center, New York, NY.
Inova Health System · USBoston Scientific (United States) · USDuke University · USMount Sinai Medical Center · USPiedmont Atlanta Hospital · USStanford University · USVanderbilt University Medical Center · US

Funding

Technological Assessment and Solutions Core - RC4P30AG021334 · NIA · JOHNS HOPKINS UNIVERSITY · PI Jeremy D Walston · 2003 to 2026
$33.2M
Frailty and Resiliency in Older Adults with Acute Myocardial InfarctionK23HL153771 · NHLBI · INOVA HEALTH CARE SERVICES · PI DAMLUJI, ABDULLA AL · 2020 to 2024
$916k
NHLBI NIH HHS K23 HL153771NIA NIH HHS P30 AG021334
6 · The paper itself

Abstract

backgroundMinorities and women are underrepresented in cardiovascular research. Whether their higher enrollment can be predicted or influences research site performance is unclear.

methodsWe evaluated 104 sites that enrolled 4,184 patients in the U.S. Platinum Diversity (PD) and Promus Element Plus (PE Plus) studies (2012 to 2016). Research sites were ranked from lowest to highest minority and female enrollment, respectively. United States Census Bureau division and core-based statistical area (CBSA) populations were determined for each site and the following study performance metrics compared across quartiles of minority and female enrollment, respectively: (1) study subject enrollment rate (SER), (2) time to first patient enrolled, (3) rate of follow-up visits not done, (4) rate of follow-up visits out of window, and (5) protocol deviation rate (PDR). Multivariable regression was used to predict SER and PDR.

resultsMinority enrollment varied by region (P = .025) and population (P = .024) with highest recruitment noted in the Pacific, West South Central, South Atlantic, Mid-Atlantic and East North Central divisions. Female enrollment bore no relationship to region (P = .67) or population (P = .40). Median SER was similar in sites withi the highest vs lowest quartile of minority enrollment (SER of 4 vs 5 patients per month, respectively, P =0.78) and highest vs. lowest female enrollment (SER of 4 vs 4, respectively, P = .21). Median PDR was lower in sites within the highest vs lowest minority enrollment (0.23 vs 0.50 PDs per patient per month, respectively, P = .01) and highest vs. lowest female enrollment (0.28 vs. 0.37 PDs per patient per month, respectively, P = .04). However, this relationship did not persist after multivariable adjustment. All other site performance metrics were comparable across quartiles of minority and female enrollment.

conclusionsMinority, but not female enrollment, correlated with research site geographic region and surrounding population. High enrollment of minorities and women did not influence study performance metrics. These findings help inform future strategies aimed at increasing clinical trial diversity.

trial registrationThe PD and PE Plus studies are registered at www.clinicaltrials.gov under identifiers NCT02240810 and NCT01589978, respectively. KEY POINTS: Question: Does the enrollment of more Blacks, Hispanics and women in US cardiovascular research studies influence the overall rate of study subject enrollment and/or other key study site performance metrics and can diverse enrollment be predicted?

findingsIn this pooled analysis of 104 sites that enrolled 4,184 patients in the Platinum Diversity and Promus Element Plus Post-Approval Studies, we found that the enrollment of higher proportions of underrepresented minorities and women was univariately associated with lower protocol deviation rates while having no effect on other site performance metrics. A site's geographic location and surrounding population predicted minority, but not female enrollment. Meaning: These findings suggest that cardiovascular research subject diversity may be predicted from site characteristics and enhanced without compromising key study performance metrics. These insights help inform future strategies aimed at improving clinical trial diversity.

Indexed as

Coronary Artery DiseasePatient SelectionPercutaneous Coronary InterventionClinical Trials as TopicDrug-Eluting StentsFemaleHealth Services AccessibilityHumansMaleMiddle AgedMinority GroupsMinority HealthOutcome Assessment, Health CareRegistriesUnited StatesWomen's Health

Identifiers

PMID33636137
PMCPMC8188231
OpenAlexW3133404555

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.